Bloodborne Pathogens Program

The purpose of the Bloodborne Pathogens Program is to minimize the risk of injury and illness to University employees who may have potential exposure to human/non-human bloodborne pathogens in research, teaching, and administrative units. This program applies to all University employees who have the potential to be exposed to human or non-human primate blood, blood products, cell lines, bodily fluids, or other potentially infectious materials. The program is designed to comply with the current Cal/OSHA Bloodborne Pathogens Standard.

1.  Bloodborne Pathogen Training is required upon assignment and annually thereafter. You may register online through Training website.  Additional training is required when working in laboratories with HIV, HBV, and HCV production.

** BBP Training slides (for annual refresher ONLY- inital training must be taken in-person)

2.  USC Exposure Control Plan describes how to eliminate or minimize exposure of all USC personnel to human/non-human primate blood or blood products that might contain bloodborne pathogens. This Exposure Control Plan demonstrates compliance with the California OSHA Bloodborne Pathogens Standard (8CCR Sec. 5193).  Each Principal Investigator (PI) or supervisor shall:  Print, review and update if necessary the Exposure Control Plan annually and as needed.  The plan shall be available to all personnel within the laboratory or work place along with the other relevant USC safety documents.


3.   In Case of a Bloodborne Pathogen Exposure:  BBP Exposure Procedure This document provides a step-by-step process of what to do in case of an accidental exposure to human blood, blood products, or human or non-human primate cell lines, or a needle-stick. 

4.  Sharps Injury Form This form is to be filled out by the injured and submitted to the Biosafety Office or Workers Compensation office within 14 days of the incident.

5.   Hepatitis B Vaccination Program

Employees who have routine exposure to human and non-human primate blood, blood products, cells, tissue and other potentially infectious material shall be offered the Hepatitis B vaccine series at no cost to themselves.